Skip to main navigation menu Skip to main content Skip to site footer

Intermittent acute porphyria: on the purpose of a case.

Porfiria aguda intermitente: a propósito de un caso




Section
Clinic cases

How to Cite
Intermittent acute porphyria: on the purpose of a case.
Rev. colomb. hematol. oncol. [Internet]. 2022 May 2 [cited 2024 Dec. 22];8(2):148-55. Disponible en: https://doi.org/10.51643/22562915.381

Dimensions
PlumX

Ana Carolina Parada Cabal,

Residente de tercer año de pediatría.


Sandra Carolina Giraldo Lora,

Pediatra


María Isabel Rodriguez Castro,

Pediatra


Luis Fernando Daza,

Médico general.


Lida Milena Araujo Cabrera,

Hematóloga y oncóloga pediatra.


Iván Mauricio Llanos Arango,

Gastroenterólogo pediatra.


Daniel Ibagón Rengifo,

Pediatra con énfasis en nutrición pediátrica.


Liliana Mejía Zapata,

Endocrinóloga pediatra.


José Fernando Gómez Urrego,

Pediatra.


Porphyrias are inherited metabolic diseases due to partial or total enzyme deficiency in the heme synthesis pathway, which leads to the accumulation of porphyrins and toxic precursors in the tissues. The clinical presentation is heterogeneous depending on the affected enzyme, with increased excretion of porphyrins and/or precursors, which allows diagnosis. In the case of acute intermittent porphyria, a deficit of porphobilinogen deaminase is established. Treatment is based on adequate metabolic intake and supply of human Hemin.  The case of a patient of 17 years of age is described, with recurrent gastrointestinal symptoms, severe hydroelectrolytic imbalance during her hospitalization, with a change in the color of urine due to sun exposure and increased porphyrins in urine, for which it is established metabolic support and later directed treatment with human hemin due to the high suspicion, obtaining several days later a report of elevated levels of Delta Amino Levulinic Acid. It is concluded that despite being a diagnosis of exclusion, it should be considered as differential, especially in the event of recurrence of symptoms, with no common etiology identified, and the rapid initiation of general measures and directed management with human hemin is necessary.


Article visits 1068 | PDF visits 1454


  1. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol [Internet]. 2017 Feb;176(4):527–38. Disponible en: http://doi.wiley.com/10.1111/bjh.14459
  2. Kauppinen R. Porphyrias. Lancet. [Internet]. 2005;365(9455):241–52. Disponible en: doi: 10.1016/S0140-6736(05)17744-7.
  3. Siegesmund M, Van Tuyll Van Serooskerken AM, Poblete-Gutiérrez P, Frank J. The acute hepatic porphyrias: Current status and future challenges. Best Pract Res Clin Gastroenterol [Internet]. 2010;24(5):593–605. Disponible en: http://dx.doi.org/10.1016/j.bpg.2010.08.010
  4. Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute intermittent porphyria: Current perspectives and case presentation. Ther Clin Risk Manag. [Internet]. 2019;15:1443–51. Disponible en: doi: 10.2147/TCRM.S180161.
  5. Cardenas JL, Guerrero C. Acute intermittent porphyria: general aspects with focus on pain. Curr Med Res Opin [Internet]. 2018;34(7):1309–15. Disponible en: https://doi.org/10.1080/03007995.2018.1435521
  6. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. [Internet]. 2015;8:201–14. Disponible en: https://doi.org/10.2147/TACG.S48605.
  7. Ramanujam VMS, Anderson KE. Porphyria diagnostics-part 1: A brief overview of the porphyrias. Curr Protoc Hum Genet. [Internet]. 2015 Jul;86:17.20.1-17.20.26. Disponible en: 10.1002/0471142905.hg1720s86
  8. Yang J, Chen Q, Yang H, Hua B, Zhu T, Zhao Y, et al. Clinical and Laboratory Features of Acute Porphyria: A Study of 36 Subjects in a Chinese Tertiary Referral Center. Biomed Res Int. [Internet]. 2016;2016:ID3927635 1-5. Disponible en: https://doi.org/10.1155/2016/3927635
  9. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E, Graziadei G, et al. A challenging diagnosis for potential fatal diseases: Recommendations for diagnosing acute porphyrias. Eur J Intern Med. [Internet]. 2014;25(6):497–505. Disponible en: https://doi.org/10.1016/j.ejim.2014.03.011
  10. Gonzalez-Aseguinolaza G. Givosiran — Running RNA Interference to Fight Porphyria Attacks. N Engl J Med. [Internet]. 2020;382(24):2366–7. Disponible en: https://doi.org/10.1056/NEJMe2010986
  11. Torregrosa L, Ayala JC, Cervera S, Villa C. La porfiria aguda intermitente y el cirujano: un reto diagnóstico: reporte de un caso y revisión de la literatura. Rev Colomb Cirugía. [Internet]. 2011;26(2):131–7. Disponible en: https://www.revistacirugia.org/index.php/cirugia/article/view/171
  12. Bustos J, Vargas L, Quintero R. Acute intermittent porphyria: A case report. Biomedica. [Internet]. 2020;40(1):14–9. Disponible en: https://doi.org/10.7705/biomedica.4767
  13. Latorre G MA. Porfiria intermitente aguda. J Bras Med. [Internet]. 2000;78(6):90–2. Disponible en: http://actamedicacolombiana.com/anexo/articulos/05-1988-03.pdf
  14. Neeleman RA, Wensink D, Wagenmakers MAEM, Mijnhout GS, Friesema ECH, Langendonk JG. Diagnostic and therapeutic strategies for porphyrias. Neth J Med. [Internet]. 2020;78(4):149–60. Disponible en: https://www.njmonline.nl/getpdf.php?id=2219
Sistema OJS 3.4.0.7 - Metabiblioteca |